Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Alessandro Parisi; Alessio Cortellini; Katia Cannita; Melissa Bersanelli; Corrado Ficorella

doi:10.1155/2019/3452762

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Case Rep Oncol Med. 2019 Feb 10:2019:3452762. doi: 10.1155/2019/3452762. eCollection 2019.

Authors

Alessandro Parisi^{1

2}, Alessio Cortellini^{1

2}, Katia Cannita¹, Melissa Bersanelli³, Corrado Ficorella^{1

2}

Affiliations

¹ Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
² Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
³ Medical Oncology, University Hospital of Parma, Parma, Italy.

Abstract

Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report the first case of a male patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab.

Publication types

Case Reports